drugset / Trial / NCT01004185
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26 weeks to children and adolescents for the maintenance of remission of ulcerative colitis.
Timeline
- Start
- 2009-10
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesalamine | Small molecule | 1.2 g | — |
| Subject | Mesalamine | Small molecule | 2 g | — |
| Subject | Mesalamine | Small molecule | 2.4 g | — |
| Subject | Mesalamine | Small molecule | 3.6 g | — |
| Subject | Mesalamine | Small molecule | 4.8 g | — |